Stay updated with breaking news from Morphosy Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds despite setbacks.
Myelofibrosis is a type of blood cancer characterized by the buildup of scar tissue, called “fibrosis,” in the bone marrow. Physicians participating in…
EQS-News: MorphoSys AG / Key word: Forecast MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces...
EQSAdhoc MorphoSys AG Key word Forecast Ad hoc MorphoSys AG Reports Preliminary 2023 Monjuvi US Net Product Sales and Gross Margin Provides 2024 Financial Guidance and Reduces Financial Liability 30J
MorphoSys AG / Key word(s): ForecastAd hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability30-Jan-2024 / 08:47 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014,...